---

Therapeutic Cancer Vaccines in Cervical Cancer: A Detailed Overview

1. Background and Rationale

---

2. Why E6 and E7 Are the Prime Targets

• Constitutively expressed in all HPV-positive cervical cancer cells
• Essential for malignant transformation - E6 degrades p53 and E7 inactivates pRb
• Foreign to the host immune system (not self-antigens), making them ideal immunotherapy targets
• Present in virtually all CIN2, CIN3, and invasive cervical cancers driven by hrHPV

---

3. Vaccine Platforms

3.1 Platform Comparison

---

4. Key Clinical Trials by Platform

4.1 DNA Vaccines

VGX-3100

• Synthetic DNA vaccine targeting HPV16 and HPV18 E6/E7
• Delivered by intramuscular injection + electroporation
• Phase IIb RCT (Trimble et al., Lancet 2015): 167 women with CIN2/3; histological regression in 49.5% vs. 30.6% placebo (p=0.034); HPV16/18 clearance 40.2% vs. 14.3%
• This remains the most advanced DNA therapeutic vaccine candidate for CIN

GX-188E

• Targets HPV16/18 E6/E7, delivered by electroporation
• Phase I/II Korean trials showed T-cell responses and lesion regression in CIN3

MEDI0457 (INO-3112) + Durvalumab

• ORR: 21% (95% CI 6%-46%)
• Disease control rate: 37%
• Median duration of response: 21.8 months
• Median OS: 17.7 months
• Grade 3-4 adverse events in 23%
• Low ORR in cervical cohort led to study discontinuation, though disease control rate was clinically meaningful

4.2 Viral Vector Vaccines

Vvax001 (Semliki Forest Virus vector)

• 18 patients, 3 immunizations (5×10⁷ infectious particles) at 3-week intervals
• Colposcopic reduction of CIN3 in 17/18 (94%)
• Histopathologic complete response (regression to ≤CIN1): 9/18 (50%)
• HPV16 clearance: 10/16 (63%)
• No serious adverse events; median disease-free survival 20 months
• Type-specific clearance only (no cross-reactive clearance of other HPV types)

MVA E2

• Modified vaccinia Ankara encoding HPV E2 protein
• Phase III data in Mexico showed regression of CIN lesions and HPV clearance in treated patients

TG4001 (MVA encoding HPV16 E6/E7/IL-2)

• Earlier studies showed regression in high-grade CIN
• Being studied in combination with avelumab (anti-PD-L1) in R/M HPV16+ cervical/anogenital cancer (Le Tourneau et al., J Clin Oncol 2025)

4.3 Peptide-Based Vaccines

ISA101 (SLP-HPV-01)

• Synthetic long peptide vaccine covering full HPV16 E6 and E7 sequences
• Phase I/II trials: robust E6/E7-specific CD4+ and CD8+ T-cell responses
• Combination with nivolumab (phase II): ~33% ORR in HPV16+ cervical cancer (Massarelli et al., Sci Transl Med 2019)
• Currently studied with checkpoint inhibitors

4.4 Recombinant Protein/Fusion Vaccines

HspE7

• Recombinant fusion protein (heat-shock protein + HPV E7)
• Phase II data in anal HSIL (HIV-negative patients): 76% regression of HSIL to LSIL in those receiving 500 µg dose; 86% remained in remission at 15 months (Maingot's)
• CD8-dependent mechanism (CD4+ T cells not involved)

Tipapkinogen Sovacivec (TA-CIN/TA-HPV combination)

• Phase II RCT in CIN2/3: evaluated over 2.5 years follow-up; modest single-agent results; investigated with adjuvants

4.5 Combination with Immune Checkpoint Inhibitors (ICI)

---

5. Mechanism of Action

HPV E6/E7 antigens presented on APC (dendritic cells)
         ↓
CD4+ T helper cell activation
         ↓
    ┌──────────────────────┐
    ↓                      ↓
CD8+ CTL activation    B-cell help (antibodies)
    ↓
HPV-infected / transformed cell killing
(perforin/granzyme + Fas-FasL pathway)

• PD-1/PD-L1 axis - upregulated in CIN3 and invasive disease
• Regulatory T cells (Tregs) - suppress effector CTL function
• TGF-β and IL-10 - immunosuppressive cytokines
• IDO pathway - tryptophan depletion suppresses T-cell function

---

6. Disease Stage and Indication

---

7. The Imiquimod-HPV Vaccine Combination (RCT Data)

• Arm A (surveillance): 79% regression to ≤CIN1
• Arm B (imiquimod alone): 95% regression - statistically significant vs. Arm A (p=0.043)
• Arm C (imiquimod + 9vHPV vaccine): 84% regression - NOT significantly better than surveillance
• Key finding: Imiquimod drove >5-fold increase in cervical tissue-resident memory CD4/CD8 T cells; adding the prophylactic vaccine did not enhance this
• Conclusion: Imiquimod alone is effective at inducing local immune responses; prophylactic HPV vaccine adds no therapeutic benefit in existing disease

---

8. Sintilimab + Prophylactic HPV Vaccine in R/M Cervical Cancer (Phase II, 2024)

• 13 patients, 2nd-line R/M cervical cancer
• Sintilimab 200 mg Q3W + HPV quadrivalent vaccine (3 doses at 0, 2, 6 months)
• ORR: 53.8% (95% CI 25.1%-80.8%)
• DCR: 76.9%
• Median PFS: 7.16 months; median OS not reached
• No Grade ≥3 treatment-related AEs
• Hypothesis: prophylactic vaccine may activate innate and adaptive immune pathways synergistically with PD-1 blockade

---

9. Emerging Platforms (2024-2026)

---

10. Guidelines and Regulatory Status

Current Guideline Position (NCCN, ESMO, WHO)

FDA-Approved Interventions for Cervical Cancer (as of 2026)

---

11. Challenges and Barriers to Clinical Translation

---

12. Summary: Stages of Evidence

---

13. Future Directions

1. Combination strategies - therapeutic vaccine + ICI + targeted therapy (e.g., anti-VEGF) is the dominant paradigm
2. mRNA platforms - leveraging COVID-19 mRNA vaccine technology to develop highly immunogenic HPV E6/E7 mRNA vaccines
3. Personalized neoantigen vaccines - beyond HPV antigens, incorporating tumor-specific mutations
4. Mucosal delivery - intranasal and intravaginal routes to activate local cervical immunity
5. Overcoming TME suppression - co-administration with TLR agonists, STING agonists, or anti-TGF-β
6. Global equity - WHO 2024 guidelines emphasize simplified dosing and low-cost production for LMIC implementation

---

• Ferrall L et al. Cervical Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 2021 [PMID: 33888488]
• Morris VK et al. Phase II Trial of MEDI0457 and Durvalumab. Oncologist 2023 [PMID: 37104874]
• Sheth SS et al. Randomized Phase II Trial of Imiquimod ± 9vHPV Vaccine. Clin Cancer Res 2024 [PMID: 38592381]
• Wang B et al. Sintilimab plus HPV vaccine for R/M cervical cancer. J Immunother Cancer 2024 [PMID: 39608975]
• Eerkens AL et al. Vvax001 Phase II Trial in CIN3. Clin Cancer Res 2025 [PMID: 39849926]
• Włoszek E et al. HPV and Cervical Cancer - Biology, Prevention, and Treatment. Curr Oncol 2025 [PMID: 40136326]
• Maingot's Abdominal Operations, 12e - Human Papillomavirus Vaccines section
• WHO Preferred Product Characteristics for Therapeutic HPV Vaccines, 2024

---

Prophylactic Cancer Vaccines in Cervical Cancer: A Detailed Overview

1. Introduction and Rationale

---

2. Currently Licensed Prophylactic HPV Vaccines

2.1 Approved Vaccines Worldwide

2.2 Mechanism of Action

• Produced from recombinant L1 capsid protein (major HPV coat protein)
• L1 spontaneously self-assembles into VLPs identical in morphology to native virions
• Completely non-infectious (contain no viral DNA)
• Adjuvant systems: Cervarix uses AS04 (MPL + Alum); Gardasil/Cervavac use AAHS (Amorphous Aluminium Hydroxyphosphate Sulfate); Gardasil 9 uses AAHS
• Stimulate high-titer neutralizing antibody responses via B-cell activation

---

3. Landmark Global Clinical Trials

3.1 Overview of Major Phase II/III Trials

---

3.2 FUTURE I Trial (Gardasil - Quadrivalent)

• Sponsor: Merck & Co.
• Phase: III (randomized, double-blind, placebo-controlled)
• Population: 5,455 women aged 16-26 years (25 countries)
• Primary endpoint: CIN (any grade), VIN, VaIN, or genital warts related to HPV 6/11/16/18
• Follow-up: ~3 years (median)
• Key results (ATP - per-protocol population):
  • 100% efficacy against HPV 6/11/16/18-related CIN, VIN, VaIN
  • 100% efficacy against HPV 6/11-related genital warts
  • 20% reduction in CIN regardless of HPV type (ITT population, reflecting real-world conditions)

---

3.3 FUTURE II Trial (Gardasil - Quadrivalent)

• Sponsor: Merck & Co.
• Phase: III (randomized, double-blind, placebo-controlled)
• Population: 12,157 women aged 15-26 years (13 countries)
• Primary endpoint: CIN2/3 or AIS (cervical adenocarcinoma in situ) related to HPV 16/18
• Follow-up: ~4 years
• Key results:
  • Per-protocol (ATP/HPV-naive): 98% efficacy against HPV 16/18-related CIN2/3
  • ITT population: 44% efficacy (reflecting prior exposure in some women)
  • No statistically significant reduction in cervical cancer (trial not powered for this; disease too rare)
  • 17% reduction in CIN2+ irrespective of HPV type (ITT)

---

3.4 PATRICIA Trial (Cervarix - Bivalent)

• Sponsor: GlaxoSmithKline
• Phase: III (randomized, double-blind, controlled)
• Population: 18,644 women aged 15-25 years (14 countries)
• Comparator: Hepatitis A vaccine (AS03-adjuvanted)
• Primary endpoint: CIN2+ associated with HPV 16/18
• Follow-up: 4+ years; extension studies ongoing

• Cervarix showed significantly greater cross-protection against non-vaccine HPV types (31, 33, 45) compared to Gardasil - attributed to its AS04 adjuvant system generating broader T-cell responses

---

3.5 CVT (Costa Rica Vaccine Trial) - Cervarix

• Sponsor: US National Cancer Institute (government-funded; not industry-sponsored)
• Phase: III community-based
• Population: 7,466 women aged 18-25 years, Guanacaste, Costa Rica
• Primary endpoint: 12-month persistent HPV 16/18 infection
• Key results (ATP):
  • 90.9% efficacy against 12-month persistent HPV16/18
  • 83.6% efficacy against anal HPV16/18 infection (first major anal efficacy data)
  • Cross-protective efficacy: 49.4% against combined HPV 31/33/45 anal infection
  • Sub-analysis: 1, 2, or 3 doses showed similar efficacy at 4-year follow-up (unexpected finding that prompted single-dose studies)

---

3.6 FUTURE III / V503 Trial (Gardasil 9 - Nonavalent)

• Sponsor: Merck & Co.
• Phase: III (randomized, double-blind, active-controlled)
• Population: 14,215 females aged 16-26 years; also Males 16-26
• Comparator: Gardasil 4v (active comparator, not placebo)
• Primary endpoint: HPV 31/33/45/52/58-related high-grade cervical/vulvar/vaginal lesions
• Key results:
  • 97.4% efficacy against HPV 31/33/45/52/58-related CIN2/3, VIN2/3, VaIN2/3
  • Non-inferior immunogenicity vs. Gardasil 4v for HPV 6/11/16/18
  • Combined HPV 6/11/16/18/31/33/45/52/58 protection covers ~90% of cervical cancers
  • 96.7% efficacy against HPV 31/33/45/52/58-related persistent infection

---

3.7 KEN SHE Trial (Single-dose; Kenya, 2023)

• Design: Multicenter, randomized, double-blind, controlled trial
• Population: 2,275 Kenyan women aged 15-20 years
• Arms: Single-dose bivalent (n=760), single-dose nonavalent (n=758), control vaccine (n=757)
• Primary outcome: Incident-persistent vaccine type-specific cervical HPV infection
• 3-year follow-up results:
  • Bivalent VE (HPV16/18): 97.5% (95% CI 90.0-99.4%, p<0.0001)
  • Nonavalent VE (HPV16/18): 98.8% (95% CI 91.3-99.8%, p<0.0001)
  • Nonavalent VE (HPV 16/18/31/33/45/52/58): 95.5% (95% CI 89.0-98.2%, p<0.0001)
  • No vaccine-related severe adverse events
• Conclusion: Single-dose HPV vaccination is highly efficacious and durable at 3 years

---

3.8 CECOLIN Trial (China)

• Cecolin (bivalent, Xiamen Innovax)
• Phase III in 7,372 Chinese women aged 18-45 years
• Efficacy against HPV16/18-related HSIL (CIN3): 100%
• Efficacy against persistent HPV16/18 infection: 97.8%
• WHO prequalified 2021; first trial data outside China (Bangladesh, Ghana 2024): non-inferior to Gardasil in girls 9-14 years

---

3.9 Cochrane Review Meta-analysis (Arbyn et al. 2018, PMID 29740819)

• CIN3+ (non-vaccine types): bivalent RR 0.08 vs. quadrivalent RR 0.54

---

3.10 Comprehensive Meta-analysis (Wang et al. 2025, PMID 41607770)

---

4. Dosing Schedules

4.1 WHO/Global Recommended Schedule (2022 onwards)

4.2 IAP Schedule in India (Current, 2025)

---

5. Indian Trials Related to HPV Vaccines

5.1 BACKGROUND: India's HPV Burden and Vaccination History

• India has the highest absolute number of cervical cancer cases globally (~77,000 cases/year, ~44,000 deaths/year as of 2020)
• HPV 16/18 account for ~75% of cases in India (slightly higher than global average)
• India's vaccination history is complex: early trials were controversially suspended in 2010

---

5.2 PATH/ICMR Demonstration Projects (Andhra Pradesh and Gujarat) - 2009-2010

---

5.3 WHO/IARC Multicentre Randomized Trial - 2 vs 3 Doses (India, 2009-2010)

---

5.4 ICMR Multicentre Cohort Study - 1, 2, and 3 Doses at 10-Year Follow-up (LANDMARK)

• Single dose provides equivalent protection to 2 or 3 doses against persistent HPV 16/18 infection at 10 years
• This was the first long-term (10-year) comparative data from a LMIC setting
• Funded by Bill & Melinda Gates Foundation
• This study was one of the key pieces of evidence that led WHO to endorse the single-dose schedule in 2022

---

5.5 Cervavac Phase 2/3 Trial (LANDMARK Indian Indigenous Vaccine Trial)

• 100% seroconversion in all initially seronegative participants for all 4 vaccine HPV types
• GMTs were >1000 times higher than baseline
• GMTs in girls/boys 9-14 years were higher than those in women 15-26 years (consistent with known immunological advantage of younger age)
• Vaccine-induced IgG GMTs at 7 months: robustly measured using multiplex VLP-based immunoassay

• Comparable solicited adverse event rates between Cervavac and Gardasil
• Most common: injection-site pain, swelling, erythema (mild to moderate)
• No serious adverse events attributable to vaccination

• Cervavac received marketing authorization from DCGI on 12 July 2022
• WHO prequalification submitted; under evaluation 2024
• Currently manufactured at 70 million doses/year; target to double by 2026
• Approximate price: ~Rs. 2,000/dose (Gardasil: ~Rs. 3,900/dose; Gardasil 9: ~Rs. 10,850/dose)

---

5.6 ICMR Single-Dose Study (2024 - Ongoing)

• Launched: November 2024
• Target: 500 girls aged 9-14 years
• Objective: Assess single-dose immunogenicity of Cervavac
• Status: Ongoing data collection

---

5.7 Cervavac Phase 3b in Women Living with HIV (Ongoing)

---

5.8 India's National HPV Vaccination Program (2024 Launch)

---

6. Efficacy Summary Across Vaccines

---

7. Side Effects and Safety Profile

7.1 Common/Expected Adverse Events

7.2 Uncommon/Rare Adverse Events (Post-Marketing Surveillance)

• 280 million doses administered globally; excellent safety profile

• No serious adverse events linked causally to HPV vaccination
• 145-RCT meta-analysis (Wang et al. 2025): serious adverse events RR 0.90 (not increased vs. control)

---

8. Contraindications and Precautions

8.1 Absolute Contraindications

8.2 Precautions

8.3 Special Populations

---

9. Vaccine Comparison Table: India-Specific

---

10. Important Cautions and Clinical Guidance

1. No therapeutic benefit: All prophylactic vaccines are ineffective against pre-existing HPV infections or established CIN/cancer. They must be administered before HPV exposure.
2. Continued screening: Vaccinated women still require regular cervical cancer screening (Pap smear, VIA, or HPV testing) as:
   • Vaccines do not protect against all hrHPV types
   • Women may have been already exposed before vaccination
   • The screening interval may be safely extended in vaccinated women per new guidelines (USPSTF 2025: primary HPV testing every 5 years preferred)
3. Do not restart the series: If the schedule is interrupted, continue from where it was stopped; do not restart.
4. Cold chain requirement: All HPV vaccines require storage at 2-8°C. Freezing inactivates the vaccine.
5. Not interchangeable: Different brands should not be mixed within the same vaccination series if possible; if necessary, document clearly and complete the series.
6. Syncope monitoring: Observe all recipients for 15 minutes post-injection due to vasovagal syncope risk, especially adolescents.
7. No benefit in active HPV infection: Goldman-Cecil Medicine states: "HPV vaccination has no therapeutic benefit against existing infections."
8. Cancer elimination target: WHO global strategy targets 90% HPV vaccination coverage of girls by age 15 by 2030 as part of the 90-70-90 strategy to eliminate cervical cancer as a public health problem.

---

Key References

• Arbyn M et al. Cochrane Database Syst Rev 2018 [PMID: 29740819]
• Wang Z et al. Front Immunol 2025 (145 RCTs meta-analysis) [PMID: 41607770]
• Basu P et al. Lancet Oncol 2021 - India 10-year dose study [PMID: 34634254]
• Sharma H et al. Lancet Oncol 2023 - Cervavac Phase 2/3 [PMID: 37949086]
• Barnabas RV et al. Nat Med 2023 - KEN SHE single-dose trial [PMID: 38049621]
• Sankaranarayanan R et al. Indian J Med Res 2016 [PMID: 27934795]
• Harrison's Principles of Internal Medicine, 22e (2025, McGraw Hill)
• Roitt's Essential Immunology, 13e
• Maingot's Abdominal Operations, 12e
• CDSCO. Cervavac SmPC. MF/BIO/22/000072 (2022)
• WHO. Global Strategy for Cervical Cancer Elimination. 2020
• IARC. Primary Endpoints for Prophylactic HPV Vaccine Trials. 2018